{"id":"brepocitinib-po-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Elevated lipids"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4747591","moleculeType":"Unknown","molecularWeight":"389.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brepocitinib selectively inhibits Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which are key mediators of inflammatory cytokine signaling. By blocking these kinases, the drug reduces the activation and proliferation of immune cells involved in autoimmune and inflammatory diseases. This mechanism is particularly relevant for conditions driven by Type I and Type II interferon signaling.","oneSentence":"Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:13.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06431373","phase":"PHASE3","title":"A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Priovant Therapeutics, Inc.","startDate":"2024-09-11","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Uveitis","enrollment":371},{"nctId":"NCT05437263","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Priovant Therapeutics, Inc.","startDate":"2022-10-31","conditions":"Dermatomyositis","enrollment":241},{"nctId":"NCT05523765","phase":"PHASE2","title":"A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis","status":"COMPLETED","sponsor":"Priovant Therapeutics, Inc.","startDate":"2022-11-14","conditions":"Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis","enrollment":26},{"nctId":"NCT06433999","phase":"PHASE2","title":"A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis","status":"COMPLETED","sponsor":"Priovant Therapeutics, Inc.","startDate":"2024-08-28","conditions":"Dermatomyositis, Dermatomyositis, Adult Type","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brepocitinib PO QD","genericName":"Brepocitinib PO QD","companyName":"Priovant Therapeutics, Inc.","companyId":"priovant-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage. Used for Systemic lupus erythematosus (SLE), Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}